According to uniQure's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 15.5365. At the end of 2023 the company had a P/S ratio of 20.4.
Year | P/S ratio | Change |
---|---|---|
2023 | 20.4 | 104.99% |
2022 | 9.97 | 444.89% |
2021 | 1.83 | -95.73% |
2020 | 42.9 | -90.04% |
2019 | 430 | 350.97% |
2018 | 95.4 | 107.23% |
2017 | 46.0 | 717.97% |
2016 | 5.63 | -85.66% |
2015 | 39.3 | -13.23% |
2014 | 45.2 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Amgen AMGN | 5.99 | -61.45% | ๐บ๐ธ USA |
Sanofi SNY | 2.44 | -84.30% | ๐ซ๐ท France |
Sangamo Therapeutics
SGMO | 0.7167 | -95.39% | ๐บ๐ธ USA |
bluebird bio
BLUE | 9.32 | -40.04% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | 5.91 | -61.94% | ๐บ๐ธ USA |
Avidity Biosciences RNA | 287 | 1,749.26% | ๐บ๐ธ USA |